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Abstract
Background: Pyrethroid insecticide-treated bed nets (ITNs) help contribute to reducing malaria deaths in Africa, but their
efficacy is threatened by insecticide resistance in some malaria mosquito vectors. We therefore assessed the evidence that
resistance is attenuating the effect of ITNs on entomological outcomes.
Methods and Findings: We included laboratory and field studies of African malaria vectors that measured resistance at the
time of the study and used World Health Organization–recommended impregnation regimens. We reported mosquito
mortality, blood feeding, induced exophily (premature exit of mosquitoes from the hut), deterrence, time to 50% or 95%
knock-down, and percentage knock-down at 60 min. Publications were searched from 1 January 1980 to 31 December 2013
using MEDLINE, Cochrane Central Register of Controlled Trials, Science Citation Index Expanded, Social Sciences Citation
Index, African Index Medicus, and CAB Abstracts. We stratified studies into three levels of insecticide resistance, and ITNs
were compared with untreated bed nets (UTNs) using the risk difference (RD). Heterogeneity was explored visually and
statistically. Included were 36 laboratory and 24 field studies, reported in 25 records. Studies tested and reported resistance
inconsistently. Based on the meta-analytic results, the difference in mosquito mortality risk for ITNs compared to UTNs was
lower in higher resistance categories. However, mortality risk was significantly higher for ITNs compared to UTNs regardless
of resistance. For cone tests: low resistance, risk difference (RD) 0.86 (95% CI 0.72 to 1.01); moderate resistance, RD 0.71 (95%
CI 0.53 to 0.88); high resistance, RD 0.56 (95% CI 0.17 to 0.95). For tunnel tests: low resistance, RD 0.74 (95% CI 0.61 to 0.87);
moderate resistance, RD 0.50 (95% CI 0.40 to 0.60); high resistance, RD 0.39 (95% CI 0.24 to 0.54). For hut studies: low
resistance, RD 0.56 (95% CI 0.43 to 0.68); moderate resistance, RD 0.39 (95% CI 0.16 to 0.61); high resistance, RD 0.35 (95% CI
0.27 to 0.43). However, with the exception of the moderate resistance category for tunnel tests, there was extremely high
heterogeneity across studies in each resistance category (chi-squared test, p,0.00001, I2 varied from 95% to 100%).
Conclusions: This meta-analysis found that ITNs are more effective than UTNs regardless of resistance. There appears to be
a relationship between resistance and the RD for mosquito mortality in laboratory and field studies. However, the
substantive heterogeneity in the studies’ results and design may mask the true relationship between resistance and the RD,
and the results need to be interpreted with caution. Our analysis suggests the potential for cumulative meta-analysis in
entomological trials, but further field research in this area will require specialists in the field to work together to improve the
quality of trials, and to standardise designs, assessment, and reporting of both resistance and entomological outcomes.
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Introduction
The World Health Organization (WHO) estimates that there
were 655,000 malaria deaths in 2010, with 86% occurring in
children under 5 y [1]. Malaria deaths are declining with the
massive scaling up of control measures, of which insecticide-
treated bed nets (ITNs) are a major component. ITNs reduce
deaths in children [2] and provide personal protection to the user,
and at scale they provide community-wide protection by reducing
the number of infective mosquitoes in the vicinity where ITNs are
used [3,4]. Between 2008 and 2010, 254 million ITNs were
supplied to countries in sub-Saharan Africa, and the proportion of
African households in possession of a net rose from 3% in 2000 to
50% by 2010 [5]. Nets, when in good condition and used
correctly, are effective, simple to use, easy to deliver to rural
communities, and cost-effective when used in highly endemic
malarious areas [6]. On account of their low mammalian toxicity,
speed of action, and high insecticidal activity, pyrethroids [7] are
the only insecticide class recommended by the WHO for use in
ITNs [8]. ITNs are effective with the African vectors Anopheles
gambiae s.s. and An. funestus in part because these species are
endophagic (feed indoors) and endophilic (rest indoors after
feeding). Aside from their insecticidal activity, pyrethroids also
exert an excito-repellency effect, which can lead to fewer
mosquitoes entering a home (deterrence) where ITNs are used,
or can cause disrupted blood feeding and premature exit of
mosquitoes from the home (induced exophily) [9]. Because of the
excito-repellency property of ITNs, these nets retain their personal
protection properties for users even after the nets become holed
[10].
The emergence and spread of insecticide resistance to all four
classes of public health insecticides (pyrethroids, organochlorines,
organophosphates, and carbamates) threatens the effectiveness of
ITNs and indoor residual house spraying. Currently, 27 countries
in sub-Saharan Africa have reported pyrethroid resistance in
Anopheles vectors [11]. The real figure could very well be higher, as
a lack of in-country resistance monitoring prevents accurate
assessment. Because of their pyrethroid dependency, ITNs are
especially vulnerable to insecticide resistance, as unlike indoor
residual house spraying there are no readily available alternative
insecticides. To prevent amplifying pyrethroid resistance, the
WHO recommends that pyrethroid insecticides should not be used
for indoor residual house spraying in areas with high long-lasting
insecticide-treated bed net (LLIN) coverage [1]. In a recent study
the extensive deployment and use of LLINs was blamed in part for
selecting resistance in Anopheles vectors in Senegal, where malaria
morbidity also increased [12]. The threat of resistance has led the
WHO and members of the Roll Back Malaria Partnership to
produce the ‘‘Global Plan for Insecticide Resistance Management
in Malaria Vectors’’, which stresses the urgency with which this
problem needs to be addressed [13].
Insecticide resistance takes multiple forms: target-site resistance,
metabolic resistance, and cuticular resistance. Target-site resis-
tance to pyrethroids in An. gambiae and An. arabiensis is underpinned
by a non-silent point mutation (either L1014F or L1014S) in the
sodium channel gene, which is referred to as the knock-down
resistance (kdr) genotype [14,15]. Target-site resistance prevents
the successful binding of the insecticide molecule to sodium
channels on the nerve membranes. Metabolic resistance is caused
by the activity of three large multi- gene families (cytochrome
P450s, glutathione transferases, and carboxylesterases) that are
able to metabolise or sequester the insecticide, thereby preventing
it from reaching its target [16]. It is becoming clear that the
cytochrome P450s are responsible for the majority of cases of
metabolic resistance, with a secondary role for the glutathione
transferases [17–20]. There is also preliminary evidence that
cuticular resistance may be a contributing factor, but this aspect
requires further analysis [17,18,21]. As pyrethroids and the
organochlorine insecticide DDT target the sodium channel
protein, cross-resistance to both insecticides is common. There is
evidence that phenotypic resistance and kdr frequency have
increased following the introduction of ITNs in some areas
[22,23], which could nullify the effectiveness of ITNs [24].
Policy makers and researchers debate whether these various
forms of resistance are having an impact on the effectiveness of
ITNs in malaria control. We carried out a systematic review of all
Box 1. Types of Studies Included
Cone Test
Methods: Studies in the laboratory in which mosquitoes
are placed inside a plastic cone that is attached to a net for
three minutes; after net exposure the mosquitoes are
placed in a holding container while entomological
outcomes are measured [25].
Outcomes: Mosquito mortality after 24 h, percentage
knock-down at 60 min, and time to 50%or 95% knock-down.
Advantages: Researchers can standardise confounding
variables, such as mosquito species, sex, age, and blood
feeding status. The number of mosquitoes used in the test
is standardised.
Tunnel Test
Methods: Studies in a laboratory, using animal bait, such as
a guinea pig, placed at one end of a specially constructed
tunnel. A fixed number of mosquitoes are released at the
other end of the tunnel, and they must pass through a
holed ITN or UTN to reach the animal bait. The following
morning, both live and dead mosquitoes, blood fed and
non-blood fed, are collected and counted from both sides
of the holed net. Live mosquitoes are monitored for a
further 24 h to assess delayed mortality [25].
Outcomes: Deterrence (not passed through net), blood
feeding, and mosquito mortality.
Advantages: As for cone test.
Field Trials
Methods: Studies in areas where mosquitoes breed.
Volunteers sleep in experimental huts for a specific period
under an ITN or an UTN, with one hut per person. The huts
are identical in construction, and incorporate exit traps to
catch wild mosquitoes entering and exiting the hut
prematurely. Each morning of the trial, both live and dead
mosquitoes, blood fed and non-blood fed, are collected
and counted from both inside the hut and the exit traps.
Live mosquitoes are monitored for a further 24 h to assess
delayed mortality. Volunteers and nets are randomly
allocated to huts at the start of the trial and are usually
rotated to avoid bias. Often huts are cleaned between
rotations to avoid cross-contamination of huts from the
different treatment arms [25].
Outcomes: Deterrence, blood feeding, mosquito mortal-
ity, and induced exophily.
Advantages: Given that this method assesses the
response of wild mosquitoes to human volunteers, it is a
more realistic representation of how effective ITNs are in
terms of entomological outcomes, compared with labora-
tory methods.
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relevant studies on human outcomes, but it became clear very
quickly that there was an almost total absence of evidence to draw
any conclusions on the impact of pyrethroid resistance on the
efficacy of nets in decreasing disease transmission. So we turned to
entomological studies: evidence of an effect of resistance on
mosquitoes could be indicative of resistance having an impac on
disease transmission. Our objective is to assess the effects of
insecticide resistance in African anopheline mosquitoes on ITNs in
terms of entomological outcomes in precise laboratory assays (cone
tests), in laboratory tests with animals (tunnel tests), and in field
trials with human volunteers as the attractants.
Methods
Inclusion Criteria
Study design. We included laboratory tests (cone tests and
tunnel tests) and field trials using experimental huts (see Box 1 for
details of types of studies included).
Mosquito population. Included African malaria vectors
were An. gambiae, An. arabiensis, or An. funestus. We included
laboratory studies that used established laboratory-colonised
strains of mosquitoes with known resistance phenotype or
genotype. Experimental hut study trials were included if they
measured the resistance status of the wild mosquito populations at
the time of the study by bioassays with our without kdr genotyping.
Intervention. We included studies that compared an ITN
(conventionally treated bed net [CTN] or a LLIN) versus an
untreated bed net (UTN). The CTNs (which require dipping into
insecticide and which also require retreatment at least once a year)
must have been impregnated with a WHO-recommended
pyrethroid with the recommended formulation and dose (see
Table 1 for recommended impregnation regimens). The LLINs
(which are factory-treated nets where the insecticide is incorpo-
rated within or bound around the net fibres) must have had either
interim or full recommendation from the WHO (see Table 2 for
recommended LLINs).
Outcomes. Included outcomes were blood feeding, mosquito
mortality, deterrence (reduction in the number of mosquitoes
found in experimental huts), induced exophily (number of
mosquitoes found in the exit trap of experimental huts), not
passed though net (measure of deterrence in tunnel test), percent
knock-down at 60 min, time to 50% knock-down, and time to
95% knock-down [25] (Table 3).
Search Strategy
The search period was from 1 January 1980 to 17 May 2013 or
later. We searched the following databases for relevant studies:
MEDLINE (from 1 January 1980 to 31 December 2013) and
Cochrane Central Register of Controlled Trials, Science Citation
Index Expanded, Social Sciences Citation Index, African Index
Medicus, and CAB Abstracts (from 1 January 1980 to 17 May
2013). There was no language restriction (see Table S1 for the
search terms used).
We also searched the following conference proceedings: First
MIM Pan-African Malaria Conference, Senegal, 6–9 January
1997; Second MIM Pan-African Malaria Conference, South
Africa, 15–19 March 1999; Third MIM Pan-African Malaria
Conference, Tanzania, 17–22 November 2002; Fourth MIM Pan-
African Malaria Conference, Cameroon, 13–18 November 2005;
Fifth MIM Pan-African Malaria Conference, Nairobi, 2–6
November 2009; American Society of Tropical Medicine and
Hygiene 59th Annual Meeting, Atlanta, Georgia, 3–7 November
2010; American Society of Tropical Medicine and Hygiene 60th
Annual Meeting, Philadelphia, Pennsylvania, 4–8 December
2011; and American Society of Tropical Medicine and Hygiene
61st Annual Meeting, Atlanta, Georgia, 11–15 November 2012.
Study Selection
Two authors (C. S. and A. A. E.) independently screened the
search results for potentially relevant studies and retrieved the
corresponding full articles. C. S. and A. A. E. independently
Table 1. WHO-recommended pyrethroids for treatment of
CTNs for vector control.
Pyrethroid Formulation Dosagea
Alpha-cypermethrin SC 10% 20–40
Cyfluthrin EW 5% 50
Deltamethrin SC 1%; WT 25%; WT 25%+binderK-ob 15–25
Etofenprox EW 10% 200
Lambda-cyhalothrin CS 2.5% 10–15
Permethrin EC 10% 200–500
aMilligrams of active ingredient per square metre of netting.
bK-O Tab 1-2-3.
CS, capsule suspension; EC, emulsifiable concentrate; EW, emulsion, oil in water;
SC, suspension concentrate; WT, water dispersible tablet.
doi:10.1371/journal.pmed.1001619.t001
Box 2. Considerations for Experimental Hut
Study Design and Reporting
Resistance Testing of Mosquito Populations:
Reporting Information Required
N Phenotypic resistance: doses of insecticide tested,
exposure times to insecticide, total number of mosqui-
toes tested, total number of mosquitoes killed
N Target-site resistance: type of mutation screened for (i.e.,
L1014F or L104S), associated kdr allele frequencies
N Metabolic resistance: identification of genes or enzyme
class implicated in conferring resistance
Study Design Reporting Criteria: Reporting
Requirement
N Study start date: date
N Study duration: number of nights
N Mosquito species present at location: species name and
molecular form
N Nets randomly allocated to huts at start of trial: yes or no
N Nets rotated between huts during trial: yes or no
N Sleepers rotated between huts during trial: yes or no
N Washing of nets: wash procedure provided
N Huts cleaned between rotations: yes or no
N Observers collecting mosquitoes blinded to intervention:
yes or no
N Sleepers blinded to intervention: yes or no
N Male mosquitoes used in the analysis: excluded or
included
N Raw data for measured outcomes: provided
N Raw data for UTNs: provided
Impact of Pyrethroid Resistance on ITN Efficacy
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assessed the articles for eligibility using a standardised form (Table
S2). Discrepancies between the eligibility results were resolved by
discussion. Study investigators were contacted for clarification if
the eligibility of a particular study was unclear. Multiple
publications from the same study were identified, and if eligible,
the original study was taken forward for inclusion.
Data Extraction
C. S. and A. A. E. independently extracted data from all
included studies into a data extraction form. Missing or unclear
outcome data were requested from the study investigators. For
dichotomous outcomes for the ITN and UTN groups, the number
of mosquitoes experiencing the outcome and the total number of
Table 2. WHO-recommended LLINs for vector control.
Product Name Product Type Status of WHO Recommendation
DawaPlus 2.0 Deltamethrin coated on polyester Interim
Duranet Alpha-cypermethrin incorporated into polyethylene Interim
Interceptor Alpha-cypermethrin coated on polyester Full
LifeNet Deltamethrin incorporated into polypropylene Interim
MAGNet Alpha-cypermethrin incorporated into polyethylene Interim
Netprotect Deltamethrin incorporated into polypropylene Interim
Olyset Permethrin incorporated into polypropylene Full
OlysetPlus Permethrin and piperonyl butoxide incorporated into polyethylene Interim
PermaNet 2.0 Deltamethrin coated on polyester Full
PermaNet 2.5 Deltamethrin coated on polyester with strengthened border Interim
PermaNet 3.0 Combination: deltamethrin coated on polyester with strengthened border (side panels)
and deltamethrin and piperonyl butoxide incorporated into polyethylene (roof)
Interim
Royal Sentry Alpha-cypermethrin incorporated into polyethylene Interim
Yorkool LN Deltamethrin coated on polyester Full
doi:10.1371/journal.pmed.1001619.t002
Table 3. Measured outcomes appropriate for the different types of study.
Outcome Description Laboratory Methods
Field Method:
Experimental Hut Trial
Cone Test Tunnel Test
Blood feeding A measure of the number of mosquitoes that have fed within a
hut or in a tunnel during a lab test. Indicates how effective an
ITN is in protecting the person sleeping under it (personal protection).
! !
Mosquito mortality Measured as the number of mosquitoes killed following exposure
to an ITN or UTN, either immediate death or delayed death (24 h
following exposure). Measured as a proportion of the total
number of mosquitoes found within a hut or placed in
tunnel/cone during a lab test. Indicates how effective an ITN
is at directly killing mosquitoes.
! ! !
Induced exophily Measured as the proportion of mosquitoes found in exit traps,
which indicates an attempt to prematurely exit the hut.
Indicates how effective an ITN is in protecting the person
sleeping under the net (personal protection).
!
Deterrence A reduction in the number of mosquitoes entering a hut using
an ITN relative to the number of mosquitoes found in a control
hut using an UTN. Indicates how effective an ITN is in protecting
the person sleeping under the net (personal protection).
!
Not pass through net Equivalent to deterrence in hut trials; measured as the number
of mosquitoes that do not pass through a holed ITN to reach
an animal bait relative to an UTN in a control test. Indicates
the potential effectiveness an ITN could have in protecting the
person sleeping under the net.
!
Knock-down at 60 min The number of mosquitoes that are knocked down (the inability of
a mosquito to fly or stand) within 60 min following exposure to a
net.
!
Time to 50% knock-down The time taken to knock down 50% of mosquitoes used in the test. !
Time to 95% knock-down The time taken to knock down 95% of mosquitoes used in the test. !
doi:10.1371/journal.pmed.1001619.t003
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mosquitoes were extracted (Tables S3–S5). For continuous
outcomes, we extracted the mean and standard deviation when
possible. For deterrence, the total number of mosquitoes was
extracted for the ITN and UTN groups. A sub-sample of 10% of
the studies was randomly selected to assess the performance of the
duplicate extraction processes by C. S. and A. A. E. Differences
between the two extraction processes were examined, and no
serious discrepancies were found. The data extracted by C. S.
were used in all analyses.
Stratification of Resistance
The WHO classifies mosquitoes as susceptible to insecticides if,
after exposure to a diagnostic dose, there is $98% mortality, and
as resistant to insecticides if there is #90% mortality; mortality
between 97% and 90% requires the confirmation of resistance
genes for mosquitoes to be classified as resistant [26]. Character-
isation of resistance across studies was not consistent, as some
studies used bioassays, others used kdr genotyping, and some used
a combination of both. We therefore developed a composite
classification system to allow us to categorise the insecticide
resistance status of mosquitoes in three broad groups (low,
moderate, and high), based on phenotypic resistance measured
using bioassay mortality data and/or kdr frequency (Table 4). The
alleles for kdr are presented as a frequency or percentage.
Risk of Bias Assessment
C. S. assessed the risk of bias of each included study. We
developed a quality assessment tool that used four criteria for
tunnel and cone tests: (1) comparability of mosquitoes in ITN and
UTN groups (all female, age matched, and non-blood fed), (2)
observers blinded, (3) complete outcome data, and (4) raw data
reported for ITN and UTN groups.
For experimental hut trials we developed seven criteria: (1)
comparability of mosquitoes in ITN and UTN huts, (2) collectors
blinded, (3) sleepers blinded, (4) raw data reported for ITN and
UTN groups, (5) ITNs randomly allocated to huts, (6) ITNs
rotated, and (7) sleepers rotated. For all criteria, we made a
judgement of high, low, or unclear risk of bias.
For hut trials, we generated an additional set of variables to
assess variability in the design and execution of the studies, called
‘‘rigor of implementation’’. The criteria assessed included (1) nets
being washed according to WHO protocol, (2) cleaning of huts
before the trial and between rotations to avoid cross-contamina-
tion of huts from the different treatment arms and to remove any
insects that may have been missed during collections, (3) whether
ITNs were tested either chemically or using bioassays to assess the
insecticide impregnation efficacy and residual activity (applicable
to CTNs), and (4) whether male mosquitoes were excluded from
the analysis. We also reported how each study measured resistance
in the wild mosquito populations: whether phenotypic resistance
was measured by bioassays and/or kdr genotyping (and the
number of mosquito screened for kdr), and whether metabolic
resistance was measured.
Data Analysis
Analyses were carried out in Review Manager 5. We stratified
the analyses by study design and the resistance status of the
mosquito population (Table 4). Dichotomous outcomes were
summarised using the RD; therefore, results are generalisable only
to situations where the UTN group event rate is comparable to
those observed here. When the same study compared multiple
ITNs, the event rate in the UTN group was split to ensure each
mosquito was included in the analysis only once.
The results of studies were pooled using meta-analysis when
possible. DerSimonian and Laird random effects models were used
when heterogeneity was detected; otherwise, a fixed effects
Mantel-Haenszel method was applied. It is worth noting that a
random effects meta-analysis awards more weight to smaller
studies than a fixed effects meta-analysis, and the weights for each
study tend to equality as the between-trial variance increases.
Assessment of Heterogeneity
Data that could not be presented in forest plots were tabulated.
Heterogeneity was assessed by visually inspecting the forest plots to
detect overlapping confidence intervals, applying the chi-squared
test with a p-value of 0.10 used to indicate statistical significance,
and implementing the I2 test statistic, with a value of 50%
indicating a moderate level of heterogeneity. Of course, such
assessments of heterogeneity are influenced by the number of
included studies and should be interpreted with caution.
Heterogeneity was substantive and common in all the analyses,
and we sought explanations through a variety of pre-specified
subgroup analyses. Subgroups included net type, type and
concentration of insecticide, and whether the net was washed or
not. We carried out sensitivity analyses by examining the effects
when analyses were restricted to hut trials that had a low risk of
bias (i.e., ITNs randomly allocated to huts, ITNs rotated, sleepers
rotated). Reporting biases were explored using funnel plots. We
calculated the confidence intervals for the I2 statistic using the
method described in [27].
Results
Search Results
Figure 1 displays the review profile. Database searches
recovered 1,107 records, from which three duplicates were
Table 4. Stratification of mosquito resistance constructed for this study based on either percent mortality from WHO bioassay
data and/or kdr frequency.
Resistance Status Percent Bioassay Mortality kdr Frequency (Percent)
High ,25 (low mortality) .80 (high kdr)
,25 (low mortality) ,25 (low kdr)
Moderate 25–80 (moderate mortality) 25–80 (moderate kdr)
25–80 (moderate mortality) ,25 (low kdr)
Low .80 (high mortality) ,25 (low kdr)
Unclear ,25 (low mortality) ,25 (low kdr)
doi:10.1371/journal.pmed.1001619.t004
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removed. Searching other sources did not yield any potentially
relevant records. After screening the 1,104 records, 914 records
were excluded. Of the remaining 73 records, 55 records were
excluded (see Figure 1 for exclusion reasons). The remaining 25
records [4,6,9,28–49] described 60 separate studies (a study is
defined as a comparison that has a distinct control UTN arm).
Results of 53 of the 60 studies were combined in a meta-analysis;
the results of five studies are described in Tables 5 and 6; and two
studies did not report useable data.
The updated MEDLINE search (May–December 2013) recov-
ered 291 records, of which two records were assessed for eligibility.
They were subsequently excluded for not meeting the study design
Figure 1. Flow diagram of the study selection process.
doi:10.1371/journal.pmed.1001619.g001
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inclusion criteria and for not characterising resistance in the
mosquito populations at the time of the study.
Characteristics of Included Studies
The 60 included studies included cone tests (n=25), tunnel tests
(n=11), and experimental hut trials (n=24).
Cone tests. The 25 included cone test studies made 60
comparisons. Characteristics for each comparison are given in
Table 7. UTNs were compared against unwashed and washed
CTNs and LLINs.
Fifty-seven comparisons used An. gambiae s.s. mosquitoes, whilst
three were of An. arabiensis. Overall, 29 comparisons used
laboratory-reared mosquito strains (Kisumu, VKPR, OC-Lab,
KWA, and RSP strains), and 28 comparisons used wild field-
caught mosquitoes from Yaokoffikro (Coˆte d’Ivoire), Muheza
(Tanzania), and localities in Uganda. Three comparisons used
recently colonised An. arabiensis mosquitoes that were originally
collected from the Ulanga District of Tanzania.
Based on the reported WHO bioassay percent mortalities and
kdr frequencies, 28 comparisons were carried out with mosquitoes
with low resistance, 20 comparisons with moderately resistant
mosquitoes, and 11 comparisons with highly resistant mosquitoes;
resistance was unclear for one comparison. Only one comparison
measured metabolic resistance.
For the risk of bias assessment, all comparisons reported
comparability of ITN and UTN mosquito groups, but it was
unclear in all studies whether observers were blinded (Table S6).
No comparison reported incomplete outcome data. Fifteen
comparisons reported raw data for ITN and UTN groups, the
remaining 45 did not.
Tunnel tests. The 11 included tunnel test studies made 20
comparisons. UTNs were compared against unwashed CTNs and
LLINs. Characteristics for each comparison are given in Table 8.
All comparisons used An. gambiae mosquitoes (the number of
mosquitoes used varied from 200 to 592). Three comparisons used
wild field-caught mosquitoes from Yaokoffikro (Coˆte d’Ivoire) and
Muheza (Tanzania) in their assessment, whilst 17 comparisons
used laboratory-reared mosquito strains (Kisumu, VKPR, Ki-
sumu/VKPR hybrids, Tola, and Kou strains). Based on the
reported WHO bioassay percent mortalities and kdr frequencies,
12 comparisons were carried out with mosquitoes with low
resistance, six comparisons used highly resistant mosquitoes, and
resistance was moderate for two comparisons. No comparison
measured metabolic resistance.
For the risk of bias assessment, 16 comparisons reported
comparability of ITN and UTN mosquito groups, whilst
comparability was unclear in four comparisons (Table S7). It
was unclear in all studies whether observers were blinded. No
comparison reported incomplete outcome data. Sixteen compar-
isons reported raw data for ITN and UTN groups, the remaining
four did not.
Experimental hut field trials. The 24 included hut studies
made 56 comparisons (Table 9). 20 comparisons used field sites in
Coˆte D’Ivoire, 14 in Tanzania, 11 in Benin, six in Burkina Faso,
and five in Cameroon. Most comparisons (41 of 56) were of An.
gambiae mosquitoes, 12 were of An. arabiensis, and three were of An.
funestus. Two comparisons used laboratory-reared strains (Kisumu).
Based on the reported WHO bioassay percent mortalities and kdr
frequencies, 26 comparisons were carried out with mosquitoes
with low resistance, 21 comparisons used highly resistant
mosquitoes, and resistance was moderate for nine comparisons.
Two comparisons measured metabolic resistance.
For the risk of bias assessment, no comparisons reported
comparability of ITN and UTN mosquito groups or blinded
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collectors of mosquitoes or the sleepers (Table S8). Forty-eight of
the 56 comparisons reported raw data for ITN and UTN groups.
It was unclear in 16 comparisons as to whether nets were
randomly allocated to huts at the start of the study. Overall, 41
comparisons rotated ITNs, eight did not, and seven did not report
rotation. Fifty comparisons rotated sleepers, whilst it was unclear
as to whether the remaining comparisons rotated the sleepers
between huts.
Table 10 displays the rigor of implementation assessment of
each hut trial in terms of particular study design characteristics.
Standardisation across studies both in terms of the experimental
design and reporting was not consistent. Of the 16 comparisons
that compared a washed net, 12 washed the net in accordance
with the WHO protocol, one did not wash the net using WHO
procedures, and it was unclear whether the remaining three had
followed WHO procedures. Seven of the 56 comparisons cleaned
the huts before the study, whereas 25 comparisons cleaned the
huts after each rotation; the remaining comparisons were unclear
regarding when the huts were cleaned. Overall, 38 of the 56
comparisons tested the ITNs before the study, 32 comparisons
tested the ITNs on completion of the study, and 22 comparisons
tested the nets chemically; the remaining comparisons did not test
the nets. Outcomes were not measured on male mosquitoes in 30
of the 56 comparisons, but were measured in the remaining 26
comparisons.
Characterisation of resistance was not consistent across studies.
Seventeen comparisons measured phenotypic resistance using
bioassays complemented with kdr genotyping in the mosquito
populations under investigation. Bioassays on their own were used
in 27 comparisons, whilst 11 comparisons were performed on
mosquitoes for which only kdr genotyping was used. Characterisa-
tion of metabolic resistance was reported in just two studies, where
the authors also measured phenotypic resistance and kdr. For those
studies which screened for kdr, ten stated the number of
mosquitoes that had been genotyped.
Relationship between Resistance and Entomological
Outcomes
Cone tests. Forty-seven cone test comparisons reported
mosquito mortality (21 low, 20 moderate, and five high resistance
and one unclear) (Figure S1). Mortality was very low in the
untreated net group, and the risk of mosquito mortality is much
higher using ITNs as compared with UTNs regardless of
resistance. The study-specific RDs showed huge variability within
all three categories of resistance. The meta-analytic results showed
that the difference in mortality risk using ITNs as compared with
UTNs decreased as resistance increased. Nevertheless, mortality
risk was significantly higher for ITNs compared to UTNs
regardless of resistance: with low resistance, the difference in risk
of mortality is 0.86 (95% CI 0.72 to 1.01; 4,626 mosquitoes, 21
comparisons; I2 = 100%, 95% CI 100% to 100%); in the case of
moderate resistance the difference in risk is 0.71 (95% CI 0.53 to
0.88; 5,760 mosquitoes, 20 comparisons; I2 = 100%, 95% CI
100% to 100%); with high resistance, the difference in risk is 0.56
(95% CI 0.17 to 0.95; 784 mosquitoes, five comparisons; I2 = 99%,
95% CI 99% to 100%). The test for subgroup differences did not
demonstrate a difference in the RD between high, medium, and
low resistance subgroups (p=0.12, I2 = 49%, 95% CI 23% to
66%). A further 12 comparisons (seven low resistance, five high)
presented data that could not be combined in meta-analysis
(Table 11).
Nine comparisons reported percentage knock-down at 60 min
(six low resistance, two high, one unclear; Figure S2). In
mosquitoes with low resistance, the risk of being knocked down
T
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Figure 2. Forest plot for experimental hut trials comparing LLIN or CTN versus UTN for blood feeding. BFaso, Burkina Faso; M-H,
Mantel-Haenszel; M.ville, Malanville (Benin); YFO, Yaokoffikro, (Coˆte d’Ivoire).
doi:10.1371/journal.pmed.1001619.g002
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Figure 3. Forest plot for experimental hut trials comparing LLIN or CTN versus UTN for mosquito mortality. BFaso, Burkina Faso; M-H,
Mantel-Haenszel; M.ville, Malanville (Benin); YFO, Yaokoffikro, (Coˆte d’Ivoire).
doi:10.1371/journal.pmed.1001619.g003
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Figure 4. Forest plot for experimental hut trials comparing LLIN or CTN versus UTN for induced exophily. BFaso, Burkina Faso; M-H,
Mantel-Haenszel; M.ville, Malanville (Benin); YFO, Yaokoffikro, (Coˆte d’Ivoire).
doi:10.1371/journal.pmed.1001619.g004
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is significantly higher using ITNs as compared with UTNs, but
with high resistance, there is no difference between ITNs and
UTNs. A significant difference is detected between the meta-
analytic results for mosquitoes with low, unclear, and high
resistance (p,0.00001, I2 = 98.8%, 95% CI 98.3% to 99.2%).
The majority of studies show that the risk of knock-down is
higher using ITNs than using UTNs, regardless of resistance. In
mosquitoes with low resistance, the difference in risk of knock-
down is 0.87 (95% CI 0.69 to 1.05; 3,440 mosquitoes, 17
comparisons; I2 = 100%, 95% CI 100% to 100%); with high
resistance, the difference in risk is 0.09 (95% CI 20.03 to 0.21;
309 mosquitoes, two comparisons; I2 = 87%, 95% CI 94% to
97%). There is high variability between the results from studies
within the same resistance category, although all comparisons tend
to favour ITNs. A further 12 comparisons (seven low resistance,
five high) presented data that could not be combined in meta-
analysis (Table 11).
Seven cone test comparisons reported time to 50% knock-down
(four low resistance, three high), and two comparisons presented
time to 95% knock-down (one low, one high). By visual inspection
of Table 5, the knock-down times tend to be longer in studies of
mosquitoes with high resistance than in studies of mosquitoes with
low resistance. However, this comparison is made across trials and
may be subject to confounding.
Tunnel tests. Fourteen tunnel test comparisons reported
feeding (eight low resistance, two moderate, six high) (Figure S3).
The higher the resistance, the lower the effectiveness of ITNs (as
compared with UTNs). A significant difference is detected
between the meta-analytic results for mosquitoes with low,
moderate, and high resistance (p=0.001, I2 = 85.1%, 95% CI
68.7% to 92.9%). A lower risk of blood feeding is apparent when
using ITNs as compared with UTNs, regardless of resistance. For
mosquitoes with low resistance, the difference in the risk of blood
feeding is 20.66 (95% CI 20.77 to 20.55; 2,177 mosquitoes,
eight comparisons; I2 = 92%, 95% CI 87% to 95%); for
mosquitoes with moderate resistance, the difference in risk is
20.53 (95% CI 20.63 to 20.42; 300 mosquitoes, two compar-
isons; I2 = 0% 95% CI not estimable); and for mosquitoes with
high resistance, the difference in risk is 20.27 (95% CI 20.45 to
20.09; 2,472 mosquitoes, six comparisons; I2 = 97%, 95% CI
94% to 98%). There is high variability among the results from
studies of mosquitoes with low resistance and also among those
from studies of mosquitoes with high resistance, although most
comparisons significantly favour ITNs. Four additional compar-
isons (low resistance) presented data that could not be combined in
meta-analysis (Table 6).
Sixteen tunnel test comparisons reported mosquito mortality
(eight low resistance, two moderate, six high) (Figure S4). The risk
of mortality is significantly higher using ITNs as compared with
UTNs, regardless of resistance. The meta-analytic results showed
that the difference in mortality risk using ITNs as compared with
UTNs decreased as resistance increased. The test for subgroup
differences showed significant variability between the meta-
analytic results from low, moderate, and high resistance subgroups
(p=0.001, I2 = 84.7%, 95% CI 67.9% to 92.7%). For mosquitoes
with low resistance, the difference in risk is 0.74 (95% CI 0.61 to
0.87; 2,177 mosquitoes, eight comparisons; I2 = 96%, 95% CI
94% to 97%); for mosquitoes with moderate resistance, the
difference in risk is 0.50 (95% CI 0.40 to 0.60; 300 mosquitoes,
two comparisons; I2 = 11%, 95% CI not estimable); and for
mosquitoes with high resistance, the difference in risk is 0.39 (95%
CI 0.24 to 0.54; 2,472 mosquitoes, six comparisons; I2 = 95%,
95% CI 94% to 98%). There is high variability among the results
from studies of mosquitoes with low resistance and also among
those from studies of mosquitoes with high resistance, yet almost
all comparisons significantly favour ITNs. Table 6 shows the
results of additional comparisons (low resistance) that could not be
combined in meta-analysis.
Six tunnel test comparisons reported whether mosquitoes could
not pass through the net (four low resistance, two high) (Figure S5).
Results show that the higher the resistance, the lower the effectiveness
of ITNs (as compared with UTNs). The observed trend could be
caused by differences in characteristics (other than resistance)
between the studies of low resistance mosquitoes and those of high
resistance mosquitoes. A significant difference is detected between the
meta-analytic results for low and high resistance mosquitoes (p,
0.00001, I2= 98.4%, 95% CI 97.1% to 99.1%).
The risk of not passing though the net is significantly higher
when using ITNs than when using UTNs, regardless of mosquito
resistance. In mosquitoes with low resistance, the difference in risk
is 0.68 (95% CI 0.62 to 0.75; 1,140 mosquitoes, four comparisons;
I2 = 61%, 95% CI 0% to 87%), and in mosquitoes with high
resistance, the difference in risk is 0.36 (95% CI 0.31 to 0.41; 1,309
mosquitoes, two comparisons; I2 = 0%, 95% CI not estimable).
There is variability among the results from studies of mosquitoes
with low resistance, yet all comparisons significantly favour ITNs.
Four additional comparisons (low resistance) presented data that
could not be combined in meta-analysis (Table 6).
Experimental hut trials. Overall, 44 hut trial comparisons
reported blood feeding (20 low resistance, nine moderate, 15 high)
(Figure 2). There is no clear relationship between resistance and
the effectiveness of ITNs. A significant difference is not detected
between the meta-analytic results for low, moderate, and high
resistance groups (p=0.84, I2 = 0%, 95% CI 0% to 35%).
Blood feeding was reduced when using ITNs as compared with
UTNs, regardless of resistance. In mosquitoes with low resistance,
the difference in the risk of blood feeding is 20.24 (95% CI 20.34
to 20.14; 11,395 mosquitoes, 20 comparisons; I2 = 97%, 95% CI
96% to 98%); in mosquitoes with moderate resistance, the
difference in risk is 20.25 (95% CI 20.31 to 20.19; 2,578
mosquitoes, eight comparisons; I2 = 46%, 95% CI 0% to 76%);
and in mosquitoes with high resistance, the difference in risk is
20.28 (95% CI 20.37 to 20.19; 8,129 mosquitoes, 16 compar-
isons; I2 = 94%, 95% CI 92% to 96%). There is particularly high
variability among the results from studies of mosquitoes with low
resistance and among those from studies of mosquitoes with high
resistance, although most comparisons significantly favour ITNs.
One comparison [22], with high resistance, reported 38% and 68%
blood feeding (figures estimated from graph) in the ITN and UTN
groups, respectively (RD=0.3).
Fifty-three hut trial comparisons reported mosquito mortality
(24 low resistance, eight moderate, 20 high) (Figure 3). There is
high heterogeneity across study-specific results with each category
of resistance. In addition, one study [9] appears to show no
evidence of an effect of ITNs in low resistance mosquitoes. The
authors also report on the bioassay, which shows 90%–100%
susceptibility to insecticides. However, mortality risk was higher
for ITNs compared to UTNs irrespective of the resistance
category. In mosquitoes with low resistance, the difference in risk
is 0.56 (95% CI 0.43 to 0.68; 67,610 mosquitoes, 24 comparisons;
I2 = 100%, 95% CI 100% to 100%); in mosquitoes with moderate
resistance, the difference in risk is 0. 39 (95% CI 0.16 to 0.61;
2,578 mosquitoes, eight comparisons; I2 = 98%, 95% CI 97% to
98%); and with high resistance, the difference in risk is 0.35 (95%
CI 0.27 to 0.43; 10,417 mosquitoes, 21 comparisons; I2 = 96%,
95% CI 95% to 97%). The meta-analytic results showed that the
difference in mortality risk using ITNs as compared with UTNs
modestly decreased as resistance increased, and the test for
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subgroup differences demonstrated a difference in the RD
between high, medium, and low resistance subgroups (p=0.03,
I2 = 72.0%, 95% CI 58.7% to 81.0%).
One comparison [22], with high resistance mosquitoes, reported
42% and 2% mortality (figures estimated from graph) in the ITN
and UTN groups, respectively (RD=0.4).
Forty-three trial hut comparisons reported results for induced
exophily (18 low resistance, nine moderate, 16 high) (Figure 4).
There is no clear relationship between resistance and the
effectiveness of ITNs in relation to this outcome. A significant
difference is detected between the meta-analytic results for low,
moderate, and high resistance (p=0.0002, I2 = 88.2%, 95% CI
81.6% to 92.3%).
Generally, the risk of exiting the hut is higher using ITNs than
using UTNs, regardless of resistance. For mosquitoes with low
resistance, the difference in risk is 0.09 (95% CI 0.04 to 0.15;
11,014 mosquitoes, 18 comparisons; I2 = 92%, 95% CI 89% to
94%); for mosquitoes with moderate resistance, the difference in
risk is 0.28 (95% CI 0.17 to 0.40; 2,578 mosquitoes, eight
comparisons; I2 = 85%, 95% CI 73% to 92%); and for mosquitoes
with high resistance, the difference in risk is 0.26 (95% CI 0.19 to
0.33; 8,695 mosquitoes, 16 comparisons; I2 = 90%, 95% CI 86%
to 93%). There is substantive heterogeneity within and across
resistance groups, but most comparisons significantly favour ITNs.
One comparison [22], with high resistance mosquitoes, reported
80% and 20% induced exophily (figures estimated from graph) in
the ITN and UTN groups, respectively (RD=0.6).
Fifty-five comparisons reported on deterrence (21 low resis-
tance, 13 moderate, 21 high) (Table 12). There is no clear
relationship between resistance status and deterrence based on a
visual inspection of the results.
Results of Subgroup Analyses, Sensitivity Analyses, and
Funnel Plots
Considerable heterogeneity was found across all studies,
therefore sources of heterogeneity were explored using subgroup
analyses. We carried out subgroup analyses by net type, insecticide
used, the concentration of insecticide, and whether nets were
washed or not. Because of the wide variation between studies in
relation to these factors, these plots were numerous. We carried
out analyses grouping in different ways, but these analyses did not
provide any explanation of the heterogeneity between studies. The
funnel plots do not resemble symmetric funnels; this may be
because of the high level of variability between studies and the low
quality of the evidence (see Figures S6–S13). For experimental hut
trials, similar conclusions are drawn from the sensitivity analyses
and primary analyses (Table S9; Figures S14–S20).
Discussion
The study set out to determine whether mosquito resistance to
insecticides is having an impact on entomological outcomes in
ITNs compared to UTNs in three experimental settings: highly
controlled cone studies, laboratory tunnel studies with animal bait,
and field trials in huts with humans as the attractant. Cone tests for
mosquito knock-down showed reduced levels of knock-down
associated with higher levels of resistance. Laboratory tunnel test
results demonstrated a reduced effect of ITNs in mosquitoes with
higher levels of resistance in terms of blood feeding, mosquito
mortality, and passage through the nets.
In experimental hut trials the RD for mortality for ITNs
compared to UTNs showed that ITNs continued to have an effect
in all categories of resistance. The meta-analytic results showed
that the difference in mortality risk using ITNs as compared with
UTNs modestly decreased as resistance increased, and the test for
subgroup differences demonstrated a difference in the RD
between high, medium, and low resistance subgroups. The
substantive heterogeneity in the studies’ results and design may
mask the true relationship between resistance and the RD, and the
results need to be interpreted with caution.
What is clear from the results is that ITNs continue to have a
substantive effect compared to UTNs in many studies, and that
despite best efforts, explaining the heterogeneity between studies
has been problematic, with field studies showing quite varied
results. Sometimes there are quite unexpected and inconsistent
findings such as in the study by Okumu et al. [9], which shows no
evidence of a benefit of insecticide despite bioassays indicating
‘‘sensitivity’’. Studies overall are very poor in characterising the
resistance pattern of the mosquitoes, and the classification systems
are unclear and lack uniformity.
We observed a large amount of heterogeneity and bias across
studies, which was particularly acute in the field studies. Variations
in the wild mosquito populations—such as their resistance levels,
age, blood feeding and mating status (factors that themselves could
influence resistance levels and host-seeking behaviour)—and also
the local environment cannot be controlled for across studies. In
addition, the execution of the field trials was not uniform across
the studies, e.g., washing of nets, rotation of nets/sleepers, season
in which the trial took place, length of the trial, decontamination
of huts, and exclusion of male mosquitoes from the analysis. Only
one field trial conducted a direct comparison of susceptible versus
resistant mosquitoes [29]. Deterrence could not be measured
because the mosquitoes were directly placed inside the huts. For
the remaining studies we conducted indirect comparisons between
trials of nets in areas of high or moderate resistance and those in
low resistance areas. Blinding of mosquito collectors, observers,
and sleepers was not addressed in any of the studies.
One area of concern is that assessment of resistance of mosquito
populations is not optimised across studies, and hence misclassi-
fication of resistance is likely to occur, adding to the high levels of
heterogeneity. It is possible that target-site and metabolic
resistance exert a differential impact on LLIN effectiveness, but
most studies fail to accurately assess the presence of metabolic
resistance. Insecticide resistance profiling of mosquito populations
was varied across all studies, with just under half of the field studies
measuring phenotypic resistance or kdr frequency, two out of the
14 studies measuring both, and only one measuring phenotypic
resistance, kdr, and metabolic resistance [50]. Phenotypic resis-
tance, as measured by bioassays, is regarded as the first step in
identifying resistance [51]. It is prudent to always carry out
bioassays to establish resistance levels before implementing
mechanistic studies (e.g., genotyping for target-site and metabolic
resistance and biochemical assays). It is unwise to assume that kdr
alone is solely responsible for the resistant phenotype [52,53];
mosquitoes could still harbour metabolic resistance, for example.
Based on this, we were reluctant to label mosquito populations
with no or low kdr frequency as ‘‘susceptible’’ (low resistance).
It is becoming increasingly clear that metabolic resistance
often underpins pyrethroid resistance in mosquitoes, as demon-
strated by both gene expression studies of resistant populations
[11,17,18,19,20,54] and enzyme characterisation studies [55,56].
To date, resistance has been directly implicated in operational
control failure of pyrethroids only in An. funestus in South Africa
[57]. Metabolic resistance is the underlying mechanism
[54,58,59], and therefore this mosquito species offers a unique
opportunity to measure the impact of resistance on ITN efficacy.
Unfortunately, none of the included studies have included the
resistant form of this species.
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A large number of studies were excluded because the insecticide
resistance status of the wild mosquito populations was not
characterised at the time of the study, but rather relied upon
retrospective data. Mosquito populations are dynamic, and
although a kdr frequency of .0.90, which is close to fixation, is
unlikely to revert rapidly, we cannot rule out the migration of
mosquito populations or other confounding factors that could
dramatically influence mosquito populations and/or resistance
profiles over time.
In terms of interpreting the patterns, this has to be done with
care, given the variability of the results. Reduced killing of
mosquitoes with increasing resistance in tunnel and hut studies
raises concerns. Feeding preferences of mosquitoes can be plastic
[60], and there is evidence that anthropogenic species such as An.
gambiae and An. funestus can switch to feeding on cattle to obtain a
blood meal in the presence of pyrethroid-treated materials [61,62].
So, although the personal protection properties of ITNs (i.e.,
prevention of blood feeding and induced exophily) are still
maintained, there is still the risk that if different hosts are
available, mosquitoes could adapt their feeding preferences and
thereby maintain large population sizes. If LLIN coverage is
lowered, nets become badly damaged, are inappropriately used,
are sold on, or are used less over time (all of which are realistic
scenarios) [63], the reduced killing of resistant mosquitoes, which
may have obtained a blood meal elsewhere, could be a cause for
concern.
Inconsistency between studies in relation to study design,
execution, and reporting format across all experimental hut trials
is an obstacle in addressing the relationship between resistance and
ITN efficacy confidently. There are no clear guidelines for
measuring ITN efficacy against resistant mosquitoes. As a
consequence, the studies do not easily lend themselves to meta-
analysis, and so it is difficult to generate a consensus. It is likely
that the effects of resistance on some outcomes may be moderate
or small, but the lack of standardisation means the methodological
differences between studies obscure any detection or coherent
synthesis between studies. So, if this field of research aims to
identify generalisable findings, then researchers need to consider
how best to measure the dependent and independent variables so
that the results are more comparable. Our concern with this lack
of transparency and standardisation, and the need for improved
reporting, echoes recent calls [64] for research to be better
planned, co-ordinated, and of higher quality. With such gaps and
lack of standardisation in the primary studies, it could be argued
that current research represents inefficient use of scarce resources
of the scientific community as a whole.
Based on the studies included in this meta-analysis, ITNs
remain at least somewhat effective against African anopheline
mosquitoes even when resistance has developed. However,
whether ITNs remain effective against resistant mosquitoes cannot
be definitively addressed whilst the execution and reporting of field
studies and the profiling of resistance in mosquito populations is
inadequate and inconsistent. Ideally, phenotypic resistance, target-
site resistance, and metabolic resistance testing should all be
applied to mosquito populations in the vicinity of the hut trial. If
this is not feasible, then a combination of either phenotypic and
target-site resistance testing or target-site and metabolic resistance
testing should be performed. Authors should make it clear in their
reporting if they have omitted to test for any of the three categories
of resistance highlighted above. It is also imperative that resistance
is measured at the time of the study rather than relying on
retrospective data. International agreement is needed for stan-
dardised methods for measuring the impact of resistance on ITNs
before conclusive statements about the effect of resistance can be
made. In order to initiate dialogue about the standardisation of
methods and reporting we have generated a list of criteria that
need to be addressed based on the experience of this review (Box
2). It is important that policy makers and non-governmental
organizations plan vector control strategies and purchase ITNs
based on the best available data.
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Editors’ Summary
Background. Every year more than 200 million cases of
malaria occur worldwide, and more than 600,000 people,
mostly children living in sub-Saharan Africa, die from this
parasitic infection. Malaria is transmitted to people through
the bites of night-flying mosquitoes. Soon after entering the
human body, the parasite begins to replicate in red blood
cells, bursting out every 2–3 days and infecting more red
blood cells. The presence of the parasite in the bloodstream
causes malaria’s recurring flu-like symptoms, which need to
be treated promptly with antimalarial drugs to prevent
anemia (a reduction in red blood cell numbers) and life-
threatening organ damage. Malaria can be prevented by
using insecticides to control the mosquitoes (vectors) that
spread the parasite and by sleeping under insecticide-
treated bed nets (ITNs) to avoid mosquito bites. High levels
of ITN use reduce malaria-related deaths among children by
about 20%. Consequently, the widespread provision of ITNs
is a mainstay of global efforts to control malaria.
Why Was This Study Done? About 50% of African
households now possess an ITN. However, the emergence
of resistance to pyrethroid insecticides—the insecticide class
recommended by the World Health Organization for use in
ITNs—in some mosquitoes potentially threatens the efficacy
of ITNs. Pyrethroids kill Anopheles mosquitoes (the main
malaria vectors in sub-Saharan Africa) but also prevent
mosquitoes entering houses (deterrence), disrupt feeding,
and encourage mosquitoes to leave homes prematurely
(‘‘induced exophily’’; Anopheles mosquitoes usually rest
inside for a while after feeding). Worryingly, 27 countries in
sub-Saharan Africa have already reported resistance to
pyrethroids in Anopheles mosquitoes. In this systematic
review and meta-analysis, the researchers assess the impact
of pyrethroid resistance on the efficacy of ITNs against
African anopheline mosquitoes in terms of entomological
outcomes. A systematic review identifies all the research on a
given topic using predefined criteria, meta-analysis uses
statistical methods to combine the results of several studies,
and entomological outcomes are measures of mosquito
behavior and survival.
What Did the Researchers Do and Find? The researchers
identified 25 reports of laboratory and field studies of the
impact of ITNs on African malaria vectors that measured the
mosquitoes’ resistance to pyrethroid insecticides at the time
of the study. The laboratory studies used two assays to
measure entomological outcomes. The cone test measured
mosquito mortality (death), percent of mosquitoes knocked
down (immobilized) after 60 minutes, and the time to knock
down 50% or 95% of the mosquitoes after brief exposure to
an ITN or untreated bed net (UTN). In the tunnel test,
mosquitoes had to pass through a holed ITN or UTN to reach
animal baits; counts of live and dead mosquitoes, and fed
and unfed mosquitoes on both sides of the net measured
deterrence, blood feeding, and mosquito mortality. In the
field studies, volunteers slept under an ITN or UTN in an
experimental hut. Subsequent counts of live and dead
mosquitoes and fed and unfed mosquitoes inside the huts
and in exit traps measured deterrence, blood feeding,
mosquito mortality, and induced exophily. The researchers
report that the measurement of insecticide resistance was
inconsistent across the identified studies. Nevertheless, their
analysis found that ITNs are more effective than UTNs in
relation to mosquito mortality, regardless of resistance.
There was a relationship between resistance and the risk
difference for mosquito mortality in laboratory and field
studies, but the substantive variation between studies means
that the findings should be interpreted with caution.
What Do These Findings Mean? These findings show
that pyrethroid resistance clearly affects entomological
outcomes in laboratory studies, and suggests that this
pattern may also be observed in field trials. However, ITNs
remained at least somewhat effective despite insecticide
resistance in terms of personal protection. The researchers
note that there was considerable variability (heterogeneity)
among the results obtained in the field trials and suggest
that poorly standardized methods and reporting might have
masked the true relationship between insecticide resistance
and ITN efficacy in these studies. Thus, although ITNs
continue to have a substantive effect in many laboratory
studies in the face of insecticide resistance, whether ITNs are
likely to remain effective against insecticide-resistant mos-
quitoes in the real world cannot be definitively concluded.
Malaria experts and vector biologists need to work together
to improve the quality of field trials and to standardize the
measurement of insecticide resistance and entomological
outcomes, suggest the researchers. Such collaborations, they
conclude, are essential to provide the data that policy
makers need to plan malaria control strategies.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001619.
N Information is available from the World Health Organiza-
tion on malaria (in several languages); the World Malaria
Report 2013 provides details of the current global malaria
situation
N Information is available from the World Health Organiza-
tion on a call for action to tackle the growing threat of
insecticide resistance and to facilitate the development of
innovative vector control tools and strategies (in English,
French and Spanish)
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish) and on
insecticide-treated bed nets; it also provides a selection of
personal stories about malaria
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria and on the
Global Malaria Action Plan (in English and French); its
website includes fact sheets about malaria in Africa and
about insecticide-treated bed nets
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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